Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating CTP-692 as an adjunctive treatment for adults with schizophrenia; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• CTP-692 (CTP-692)

Snippet

Sponsor: Concert Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2023-12-22